Mar 18, 2026

Dane Stevens, Founder, CEO, and Director at Optimi Health, a Canadian company that manufactures MDMA and naturally derived psilocybin from mushrooms for use in therapy for PTSD and treatment-resistant depression. These psychedelic-based mental health treatments are being used in the regulated market in Australia and in...

Mar 18, 2026

Dane Stevens, Founder, CEO, and Director at Optimi Health, a Canadian company that manufactures MDMA and naturally derived psilocybin from mushrooms for use in therapy for PTSD and treatment-resistant depression. These psychedelic-based mental health treatments are being used in the regulated market in Australia and in...

Dec 17, 2024

Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth.  A phase two trial is underway to evaluate how RE-104, a rapid-acting...

Dec 17, 2024

Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth.  A phase two trial is underway to evaluate how RE-104, a rapid-acting...

Apr 23, 2024

Dr. Kazu Okuda, Founder, and CEO of Universal Brain, uses neurotyping based on EEG data to better understand the different types of depression and deliver more precise treatments. To facilitate the availability of EEG data, Universal Brain has developed a next-generation EEG headset that is affordable and comfortable....